These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35644844)

  • 1. Progression and treatment of a series of patients with advanced LRRK2-associated Parkinson's disease.
    Fernández-Pajarín G; Sesar Á; Jiménez-Martín I; Ares B; Castro A
    Neurologia (Engl Ed); 2023 Jun; 38(5):350-356. PubMed ID: 35644844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and treatment of a series of patients with advanced LRRK2-associated Parkinson's disease.
    Fernández-Pajarín G; Sesar Á; Jiménez-Martín I; Ares B; Castro A
    Neurologia (Engl Ed); 2021 Feb; ():. PubMed ID: 33541803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease.
    Prendes Fernández P; Blázquez Estrada M; Sol Álvarez J; Álvarez Martínez V; Suárez San Martín E; García Fernández C; Álvarez Carriles JC; Lozano Aragoneses B; Saiz Ayala A; Santamarta Liébana E; González Álvarez L
    Parkinsonism Relat Disord; 2023 Feb; 107():105282. PubMed ID: 36657280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
    Ahamadi M; Mehrotra N; Hanan N; Lai Yee K; Gheyas F; Anton J; Bani M; Boroojerdi B; Smit H; Weidemann J; Macha S; Thuillier V; Chen C; Yang M; Williams-Gray CH; Stebbins GT; Pagano G; Hang Y; Marek K; Venuto CS; Javidnia M; Dexter D; Pedata A; Stafford B; Akalu M; Stephenson D; Romero K; Sinha V;
    Clin Pharmacol Ther; 2021 Aug; 110(2):508-518. PubMed ID: 33894056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
    Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
    BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
    Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease.
    Leaver K; Viser A; Kopell BH; Ortega RA; Miravite J; Okun MS; Elango S; Raymond D; Bressman SB; Saunders-Pullman R; Luciano MS
    J Neurosurg; 2022 Jul; 137(1):184-191. PubMed ID: 34798606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.